Tocilizumab 托珠单抗; Anti-Human IL6R, Humanized Antibody|cas:375823-41-9|西域试剂

Tocilizumab 托珠单抗; Anti-Human IL6R, Humanized Antibody,99.67%

产品编号：Bellancom-P9917| CAS NO：375823-41-9| 分子式：| 分子量：

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P9917		￥2700.00	杭州北京（现货）
Bellancom-P9917		￥5700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Tocilizumab 托珠单抗; Anti-Human IL6R, Humanized Antibody

产品介绍

Tocilizumab (Anti-Human IL6R, Humanized Antibody) 是一种抗人白细胞介素-6 受体 (IL-6R) 的中和抗体，可阻止 IL-6 与 IL-6R 的结合，从而抑制经典和反式信号。Tocilizumab 可用于类风湿性关节炎的相关研究。Tocilizumab 在重症 COVID-19 病毒方面的研究效果显著。

生物活性

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)^[4].

体外研究

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab.
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC₅₀ of 13.5 ng/ml.
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells.
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	Human-derived HARA-B cells
Concentration:	1 ng/mL, 10 ng/mL, and 100 ng/mL
Incubation Time:	24 hours, 48 hours
Result:	Inhibited the IL-6R expressed on human-derived HARA-B cells.

Cell Cytotoxicity Assay

Cell Line:	Ba/F3-gp130-IL-6R cells
Concentration:	0.001–10000 μg/ml
Incubation Time:	2 days
Result:	Inhibited Ba/F3-gp130-IL-6R cell proliferation.

Western Blot Analysis

Cell Line:	SAS cells
Concentration:	1 μM
Incubation Time:	6 hours
Result:	Reduced the phosphorylation of STAT3.

RT-PCR

Cell Line:	SAS cells
Concentration:	1-5 μM
Incubation Time:	24 hours
Result:	Reduced VEGF mRNA expression.

体内研究
(In Vivo)

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains.
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice
Dosage:	1.0 mg/100 μL
Administration:	Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
Result:	Led the volume of each metastatic focus significantly smaller.

Animal Model:	SCID mice with SAS cells
Dosage:	100 μg/mL
Administration:	Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
Result:	Suppressed the growth of advanced tumors.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice
Dosage:	1.0 mg/100 μL
Administration:	Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
Result:	Led the volume of each metastatic focus significantly smaller.

Animal Model:	SCID mice with SAS cells
Dosage:	100 μg/mL
Administration:	Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
Result:	Suppressed the growth of advanced tumors.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice
Dosage:	1.0 mg/100 μL
Administration:	Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
Result:	Led the volume of each metastatic focus significantly smaller.

Animal Model:	SCID mice with SAS cells
Dosage:	100 μg/mL
Administration:	Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
Result:	Suppressed the growth of advanced tumors.

性状

Liquid

溶解性数据

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70. [Content Brief]

. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526. [Content Brief]

. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34. [Content Brief]

[4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

1. 物质的识别

产品名：	Tocilizumab
CAS号：	375823-41-9
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Tocilizumab
别名：	MRA; atlizumab
分子式：	C6428H9976N1720O2018S42
分子量：	144984.63

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	-80°C for long term

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

Tocilizumab 托珠单抗; Anti-Human IL6R, Humanized Antibody,99.67%

Tocilizumab 托珠单抗; Anti-Human IL6R, Humanized Antibody

化学品安全说明书(MSDS)

质检证书(COA)

1. 物质的识别

2. 合成/成分数据

3. 急救措施

4. 消防措施

5. 泄漏应急处理

6. 处理和储存

7. 接触控制和个人防护

8. 稳定性和反应活性

9. 毒性资料

10. 生态资料

11. 废弃处置

12. 运输信息

13. 法规信息

14. 其他信息

在线咨询